GHK-Cu is the copper(II) complex of the naturally occurring human tripeptide glycyl-L-histidyl-L-lysine (GHK), studied in the research literature as a copper-binding matrikine implicated in extracellular-matrix remodeling and tissue repair. The parent peptide was first traced to a copper-avid serum factor isolated from human plasma in 1973, and the complex has since become one of the most extensively characterized copper peptides. This monograph summarizes its chemistry, reported mechanisms, and published findings across in-vitro, animal, and large-scale transcriptomic models. It is presented strictly for laboratory and research use.

Background & Discovery

GHK-Cu is the copper(II) complex of the naturally occurring human tripeptide glycyl-L-histidyl-L-lysine (GHK). The free peptide was first isolated in 1973 by Loren Pickart from human plasma while investigating a serum factor that altered the behavior of cultured hepatocytes; the activity was subsequently traced to the GHK sequence and its avid affinity for copper. Because the GHK motif also occurs within the α-2(I) chain of type I collagen and in SPARC/osteonectin, the literature frames it as a fragment that can be liberated by proteolysis at sites of tissue injury, where it is thought to act locally as a copper-delivery and signaling molecule.

GHK is present in human plasma, saliva, and urine, and multiple reviews report that its plasma concentration declines with age (cited figures fall from roughly 200 ng/mL in early adulthood to about 80 ng/mL by the seventh decade). This age-associated decline, combined with copper’s role as a cofactor for enzymes such as lysyl oxidase and superoxide dismutase, is why the peptide is studied as a model system for extracellular-matrix (ECM) remodeling, wound repair, and the biology of aging tissue rather than as a single-target drug.

Within research-chemical and cosmetic-science literature, GHK-Cu is categorized as a copper-binding matrikine/matricryptin. It is one of the most extensively characterized copper peptides, with a body of work spanning fibroblast and keratinocyte cultures, rodent and rabbit wound models, ex-vivo human skin, and large-scale gene-expression (Connectivity Map / Broad Institute) analyses. It is investigated strictly as a laboratory research compound; the summaries below describe what published studies report in defined experimental models and do not constitute medical guidance.

Chemical Identity

Structure & Physicochemical Properties

In its purified form GHK-Cu is typically supplied as a blue to blue-violet crystalline or lyophilized powder, the color arising from the d-d electronic transitions of the coordinated Cu(II) center. The intense visible absorbance (a broad band in the ~500-600 nm region) is a convenient qualitative marker of copper coordination. The complex is readily water-soluble, and the peptide backbone is highly polar owing to the free α-amino group of glycine, the imidazole side chain of histidine, and the ε-amino group of lysine. Copper is held in a stable, roughly square-planar arrangement using the N-terminal amine, the deprotonated peptide-bond nitrogen, and the histidine imidazole nitrogen as principal donor atoms, giving the complex a very high formal stability constant that allows it to compete for copper with serum albumin under physiological-like conditions.

The free peptide (C₁₄H₂₄N₆O₄, 340.38 g/mol) is comparatively stable, while the copper complex is sensitive to strong reducing agents, extremes of pH, and chelators that can strip or reduce the metal. Reported literature notes that the exact molecular formula and mass depend on protonation state and counter-ions (acetate salts are common), which is why databases list the cationic complex as C₁₄H₂₃CuN₆O₄⁺ (approx. 402.9 g/mol) while the neutral 1:1 complex is often written C₁₄H₂₂CuN₆O₄. Stoichiometry (1:1 GHK:Cu) and metal loading are important physicochemical descriptors that distinguish authentic GHK-Cu from a simple physical mixture of peptide and copper salt.

Mechanism of Action — as described in the literature

The primary and best-characterized feature of GHK-Cu is its coordination chemistry. GHK binds Cu(II) with high affinity through the glycine α-amino nitrogen, the adjacent deprotonated amide nitrogen, and the histidine imidazole, forming a thermodynamically stable chelate. Published work characterizes GHK as a physiological copper shuttle able to exchange copper with albumin and to facilitate copper uptake by cells, thereby modulating the availability of a metal that serves as a catalytic cofactor for enzymes including lysyl oxidase (collagen/elastin cross-linking) and Cu/Zn superoxide dismutase (antioxidant defense). Much of the downstream biology is interpreted as a combination of direct peptide signaling and controlled delivery of bioavailable copper.

A central theme in the ECM literature is that GHK-Cu acts as a balanced modulator of matrix turnover rather than a one-directional stimulant. In fibroblast cultures the complex stimulates de novo synthesis of collagen and of glycosaminoglycans and proteoglycans (including dermatan sulfate, chondroitin sulfate, and decorin), with reported activity in the picomolar-to-nanomolar range. In parallel, wound-model studies show that GHK-Cu regulates matrix metalloproteinases (notably increasing pro-MMP-2 and its activation) while also influencing their endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). This dual control of synthesis and remodeling is the mechanistic basis for the recurring description of GHK-Cu as a ’tissue-remodeling’ peptide.

Beyond ECM proteins, large-scale transcriptomic analyses recast GHK as a broad modulator of gene expression. Using the Connectivity Map, investigators reported that GHK can shift the expression of thousands of human genes, and reviews summarize that it can up- or down-regulate on the order of 4,000 genes, frequently moving pathological expression patterns toward those of healthy tissue. Enriched pathways include the transforming growth factor-β (TGF-β) program, actin cytoskeletal organization, integrin signaling, DNA repair, antioxidant response, and ubiquitin-proteasome-mediated protein turnover.

GHK-Cu is also linked to angiogenic and growth-factor signaling. In endothelial and wound models the complex is associated with increased vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2), enhanced endothelial proliferation, and recruitment of repair cells, supporting new capillary formation during granulation. These pro-angiogenic and chemotactic actions are typically reported alongside its ECM effects as part of a coordinated repair phenotype.

Finally, the peptide has a well-documented antioxidant and anti-inflammatory profile in the literature. Reported mechanisms include quenching of reactive oxygen and reactive carbonyl species, detoxification of lipid-peroxidation products such as acrolein, modulation of iron-driven oxidative damage, support of superoxide dismutase activity, and reduction of pro-inflammatory mediators including TNF-α and NF-κB-associated signaling. Because these effects operate across multiple, partially independent pathways, current reviews describe GHK-Cu’s mechanism as pleiotropic and gene-level rather than attributable to a single receptor.

Key Published Findings

• Collagen synthesis in fibroblasts (in vitro): In cultured fibroblasts, the GHK-Cu²⁺ complex stimulated collagen synthesis with activity beginning between 10⁻¹² and 10⁻¹¹ M and maximizing near 10⁻⁹ M, independent of any change in cell number, indicating a direct effect on matrix production rather than proliferation.[2]
• MMP/TIMP modulation in wound remodeling: In an experimental wound model, GHK-Cu increased levels and activation of pro-MMP-2 during the later remodeling phase (days 18-22) with minimal effect on interstitial collagenase, and modulated metalloproteinase inhibitors, supporting a role in controlled extracellular-matrix remodeling.[3]
• Emphysema/COPD gene-expression signature (human tissue + fibroblasts): Using the Connectivity Map, GHK was identified as a compound that reverses the gene-expression signature of emphysematous lung destruction; treatment of fibroblasts recapitulated TGF-β-induced patterns, organized the actin cytoskeleton, raised integrin β-1, and restored collagen I contraction in COPD-derived fibroblasts.[4]
• Genome-scale modulation of nervous-system genes (in silico/transcriptomic): Transcriptomic analysis reported that GHK induced a 50% or greater change in expression of roughly 31.2% of assayed human genes, up-regulating 408 and down-regulating 230 neuron-associated genes and affecting pathways for nerve outgrowth, DNA repair, antioxidant systems, and protein clearance.[6]
• In vivo wound healing (rabbit model): Topical tripeptide-copper complex produced significantly smaller unhealed wound areas by day 7, faster wound contraction, shorter time to granulation-tissue coverage, and superior neovascularization compared with zinc oxide and untreated controls.[9]
• Angiogenesis and scald-wound repair (mouse model): GHK-Cu-loaded liposomes increased human umbilical vein endothelial cell proliferation by ~33%, enhanced VEGF and FGF-2 expression, and in a murine scald model improved angiogenesis (CD31, Ki67) and shortened healing time relative to free GHK-Cu.[10]
• Collagen IV upregulation and synergy (fibroblast + ex-vivo skin): Combining GHK-Cu with low-molecular-weight hyaluronic acid at a 1:9 ratio synergistically elevated collagen IV synthesis by 25.4-fold in a fibroblast cell test and 2.03-fold in an ex-vivo skin test, relevant to dermal-epidermal junction biology.[11]

Research Applications

• Investigated in fibroblast culture systems as a model modulator of extracellular-matrix synthesis (collagen, elastin, glycosaminoglycans, and decorin).
• Examined in rodent, rabbit, and murine cutaneous wound-healing models for effects on contraction, granulation, and neovascularization.
• Studied in endothelial-cell and angiogenesis assays for its association with VEGF/FGF-2 signaling and capillary formation.
• Used in skin-aging and photodamage research, including ex-vivo human skin and dermal fibroblast models of collagen and MMP/TIMP regulation.
• Applied as a probe in genome-wide and Connectivity Map transcriptomic studies of gene-expression ‘resetting,’ including emphysema/COPD lung-tissue signatures.
• Investigated in neurobiology research on gene expression relevant to nervous-system function, neuroinflammation, and cognitive-decline models.
• Employed in oxidative-stress and antioxidant-enzyme studies (e.g., superoxide dismutase activity, reactive carbonyl and lipid-peroxidation product detoxification).
• Used as a model system for copper coordination chemistry and physiological copper homeostasis, including copper exchange with serum albumin.
• Explored in in-vitro cancer-cell gene-modulation studies (e.g., MCF7 breast and PC3 prostate lines) as a research tool, not a therapeutic.

Related & Comparator Compounds

The most directly related molecule is the free tripeptide GHK (glycyl-L-histidyl-L-lysine, CAS 49557-75-7), which shares the same peptide backbone but lacks the coordinated copper; the literature generally attributes much of the ECM-remodeling and gene-modulating activity to the copper-loaded form, while noting that the apo-peptide can still bind endogenous copper. Related copper-binding motifs include the amino-terminal Cu/Ni-binding (ATCUN) sequences of serum albumin (Asp-Ala-His) and the SPARC-derived and collagen-derived GHK-containing fragments from which the peptide is thought to be released. In cosmetic and research comparisons, GHK-Cu is frequently contrasted with signal peptides such as palmitoyl pentapeptide (Matrixyl / pal-KTTKS) and copper-free matrikines, which act on collagen signaling without delivering a metal cofactor. It is also commonly discussed alongside BPC-157 in tissue-repair reviews, though the two differ entirely in structure and proposed mechanism. Within the broader copper-peptide class, GHK-Cu is distinguished by its very high copper-affinity constant, its documented bidirectional control of matrix synthesis and degradation, and the unusually large transcriptomic footprint reported for it.

Handling, Reconstitution & Storage

In research settings GHK-Cu is typically supplied as a lyophilized powder and is described as being reconstituted in sterile or bacteriostatic water, or in dilute aqueous buffer, to prepare stock solutions for in-vitro or preclinical work; the intact blue-violet color is often used as an at-a-glance indicator that the copper remains coordinated. Published handling practice for research copper peptides emphasizes storing the lyophilized solid desiccated and protected from light at −20°C (or lower for long-term storage), keeping reconstituted aliquots refrigerated and using them promptly, and avoiding repeated freeze-thaw cycles that can degrade the peptide or perturb the metal complex. Strong reducing agents, chelating buffers (e.g., EDTA), and extremes of pH should be avoided because they can strip or reduce the copper center. All of the above pertains solely to laboratory handling of a research chemical and is not human-use guidance.

Analytical & Quality Considerations

Quality control for GHK-Cu characteristically combines peptide-purity and metal-complex verification. Reversed-phase HPLC (with UV detection) is used to establish chromatographic purity, typically reported at ≥98%, while mass spectrometry (ESI-MS or MALDI-TOF) confirms identity against the expected mass of the GHK backbone (340.38 g/mol for the free peptide) and the copper adduct. Because a genuine complex differs from a physical peptide/copper-salt mixture, orthogonal confirmation of copper content and stoichiometry is important and is commonly performed by ICP-MS, ICP-OES, or atomic absorption spectroscopy, supported by the characteristic UV-Vis d-d absorption band that reflects intact Cu(II) coordination. Amino-acid analysis or sequencing can confirm the Gly-His-Lys sequence, and residual-solvent, water-content, and endotoxin testing may accompany research-grade material. Because label claims are not independently guaranteed, an independent third-party certificate of analysis (COA) documenting identity, HPLC purity, mass confirmation, and copper stoichiometry is the standard way researchers verify that a supplied lot matches specification.

Frequently Asked Research Questions

Q. What is GHK-Cu and where does it come from?
A. GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine (GHK). The free peptide was first isolated from human plasma in 1973 and also occurs within type I collagen and SPARC, from which it can be released by proteolysis. It is studied as a naturally occurring copper-binding matrikine and, for research purposes only, as a laboratory reference compound.

Q. How does GHK-Cu differ from GHK without copper?
A. They share the same tripeptide sequence, but GHK-Cu carries a bound Cu(II) ion coordinated by the glycine amine, an amide nitrogen, and the histidine imidazole. Published literature attributes much of the extracellular-matrix and gene-modulating activity to the copper-loaded form, in part because the complex can deliver bioavailable copper and act as a copper shuttle; the apo-peptide can still chelate endogenous copper.

Q. What models is GHK-Cu most studied in?
A. The strongest evidence base is in fibroblast and keratinocyte cultures, rodent and rabbit wound-healing models, ex-vivo human skin, endothelial/angiogenesis assays, and large-scale gene-expression (Connectivity Map) analyses, including an emphysema lung-tissue study. Neurobiology and oxidative-stress transcriptomic studies have also used it as a probe.

Q. What does ’tissue remodeling’ mean in the GHK-Cu literature?
A. It refers to the peptide’s reported ability to modulate both the synthesis and the breakdown of the extracellular matrix simultaneously: stimulating collagen and glycosaminoglycan production in fibroblasts while also regulating matrix metalloproteinases (such as MMP-2) and their inhibitors (TIMPs). Researchers describe this balanced, bidirectional control as characteristic of a remodeling peptide.

Q. How is GHK-Cu identity and purity verified in a lab?
A. Typical QC uses reversed-phase HPLC for purity (commonly reported at 98% or higher), mass spectrometry for identity, and copper-specific methods (ICP-MS/OES or atomic absorption) plus the characteristic UV-Vis absorption band to confirm intact copper coordination and 1:1 stoichiometry. An independent third-party certificate of analysis is the standard verification document.

Q. Is GHK-Cu approved as a drug?
A. This monograph describes GHK-Cu as a laboratory research chemical. The peptide has appeared in pharmacopeial and cosmetic-ingredient contexts (e.g., as copper tripeptide-1 / prezatide copper), and the scientific literature includes clinical-pharmacology and cosmetic studies, but nothing here should be read as medical guidance, dosing, or a therapeutic claim.

Peer-Reviewed References

1. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008. PubMed →
2. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Letters. 1988. PubMed →
3. Siméon A, Monier F, Emonard H, Gillery P, Birembaut P, Hornebeck W, Maquart FX. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. Journal of Investigative Dermatology. 1999. PubMed →
4. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, Suzuki M, Gosselink JV, Liu G, Alekseyev YO, et al.. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012. PubMed →
5. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity. 2012. PubMed →
6. Pickart L, Vasquez-Soltero JM, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sciences. 2017. PubMed →
7. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018. PubMed →
8. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015. PubMed →
9. Cangul IT, Gul NY, Topal A, Yilmaz R. Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Veterinary Dermatology. 2006. PubMed →
10. Wang X, Liu B, Xu Q, Sun H, Shi M, Wang D, Guo M, Yu J, Zhao C, Feng B. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair and Regeneration. 2017. PubMed →
11. Jiang F, Wu Y, Liu Z, Hong M, Huang Y. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. Journal of Cosmetic Dermatology. 2023. PubMed →

For laboratory and research use only. Not for human or veterinary use, diagnosis, or treatment. This overview summarizes published scientific literature for informational and educational purposes and is not medical advice; no claims are made regarding safety or efficacy in humans.

← Back to the Research Library · View GHK-Cu → · COA & Testing